MSD SUB MERCK Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MSD SUB MERCK, and what generic alternatives to MSD SUB MERCK drugs are available?
MSD SUB MERCK has fourteen approved drugs.
There are twenty US patents protecting MSD SUB MERCK drugs.
There are five hundred and forty-nine patent family members on MSD SUB MERCK drugs in sixty countries and one hundred and fifty-eight supplementary protection certificates in nineteen countries.
Summary for MSD SUB MERCK
International Patents: | 549 |
US Patents: | 20 |
Tradenames: | 13 |
Ingredients: | 11 |
NDAs: | 14 |
Drugs and US Patents for MSD SUB MERCK
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Sub Merck | INTEGRILIN | eptifibatide | INJECTABLE;INJECTION | 020718-001 | May 18, 1998 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Msd Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-002 | Dec 15, 2015 | AP | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Msd Sub Merck | ISENTRESS | raltegravir potassium | TABLET, CHEWABLE;ORAL | 203045-001 | Dec 21, 2011 | RX | Yes | No | 7,754,731*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Msd Sub Merck | ISENTRESS | raltegravir potassium | TABLET;ORAL | 022145-001 | Oct 12, 2007 | RX | Yes | Yes | 7,754,731*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MSD SUB MERCK
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Msd Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-002 | Dec 15, 2015 | 6,949,527 | ⤷ Subscribe |
Msd Sub Merck | JANUMET XR | metformin hydrochloride; sitagliptin phosphate | TABLET, EXTENDED RELEASE;ORAL | 202270-003 | Feb 2, 2012 | 6,890,898 | ⤷ Subscribe |
Msd Sub Merck | JANUMET XR | metformin hydrochloride; sitagliptin phosphate | TABLET, EXTENDED RELEASE;ORAL | 202270-002 | Feb 2, 2012 | 7,078,381 | ⤷ Subscribe |
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RE38506 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MSD SUB MERCK drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 2 mg/mL, 100 mL vial | ➤ Subscribe | 2008-12-18 |
➤ Subscribe | Injection | 1 g/vial | ➤ Subscribe | 2013-06-20 |
➤ Subscribe | Ophthalmic Solution | 2% | ➤ Subscribe | 2005-10-11 |
➤ Subscribe | Extended-release Tablets | 100 mg/1000 mg | ➤ Subscribe | 2012-10-22 |
➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2008-09-30 |
➤ Subscribe | Injection | 0.75 mg/mL, 100 mL vial | ➤ Subscribe | 2009-06-05 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2011-10-12 |
➤ Subscribe | Extended-release Capsules | 50 mg/500 mg and 50 mg/1000 mg | ➤ Subscribe | 2012-03-16 |
➤ Subscribe | Tablets | 50 mg/500 mg and 50 mg/1000 mg | ➤ Subscribe | 2010-10-18 |
International Patents for MSD SUB MERCK Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
New Zealand | 555120 | ⤷ Subscribe |
Australia | 776536 | ⤷ Subscribe |
Hungary | S1700001 | ⤷ Subscribe |
South Korea | 20130140219 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for MSD SUB MERCK Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2310095 | 2017004 | Norway | ⤷ Subscribe | PRODUCT NAME: GRAZOPREVIR ELLER ET; REG. NO/DATE: EU/1/16/1119 20160804 |
2310095 | 2/2017 | Austria | ⤷ Subscribe | PRODUCT NAME: GRAZOPREVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1119 (MITTEILUNG) 20160726 |
1412357 | SPC/GB08/040 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716 |
1441735 | C20080001 | Estonia | ⤷ Subscribe | PRODUCT NAME: ISENTRESS; AUTHORISATION NO.: EMA/106827/2018; AUTHORISATION DATE: 20180222 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.